Advertisement
ATYR vs KPRX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATYR is a Buy and KPRX is a Hold.
ATYR in upward trend: price may jump up because it broke its lower Bollinger Band on October 12, 2026
ATYR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 35 of 44 cases where ATYR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATYR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for ATYR entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.348) is normal, around the industry mean (3.009). P/E Ratio (-0.275) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (196.078) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. ATYR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATYR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
KPRX sees MACD Histogram just turned negative
KPRX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 29, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 45 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KPRX as a result. In 89 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
KPRX moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for KPRX crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for KPRX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where KPRX advanced for three days, in 187 of 238 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
KPRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.617) is normal, around the industry mean (2.978). P/E Ratio (-0.992) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (0.823) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. KPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KPRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ATYR | KPRX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 52 | 91 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 56 Fair valued | 39 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 98 | |
PRICE GROWTH RATING 1..100 | 96 | 50 | |
P/E GROWTH RATING 1..100 | 7 | 29 | |
SEASONALITY SCORE 1..100 | 30 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KPRX's Valuation (39) in the Pharmaceuticals Other industry is in the same range as ATYR (56) in the null industry. This means that KPRX’s stock grew similarly to ATYR’s over the last 12 months.
KPRX's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ATYR (100) in the null industry. This means that KPRX’s stock grew similarly to ATYR’s over the last 12 months.
KPRX's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as ATYR (99) in the null industry. This means that KPRX’s stock grew similarly to ATYR’s over the last 12 months.
KPRX's Price Growth Rating (50) in the Pharmaceuticals Other industry is somewhat better than the same rating for ATYR (96) in the null industry. This means that KPRX’s stock grew somewhat faster than ATYR’s over the last 12 months.
ATYR's P/E Growth Rating (7) in the null industry is in the same range as KPRX (29) in the Pharmaceuticals Other industry. This means that ATYR’s stock grew similarly to KPRX’s over the last 12 months.
| ATYR | KPRX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 79% | N/A |
| Stochastic ODDS (%) | N/A | 2 days ago 89% |
| Momentum ODDS (%) | N/A | 2 days ago 90% |
| MACD ODDS (%) | N/A | 2 days ago 90% |
| TrendWeek ODDS (%) | 1 day ago 86% | 2 days ago 90% |
| TrendMonth ODDS (%) | 1 day ago 85% | 2 days ago 90% |
| Advances ODDS (%) | N/A | 9 days ago 79% |
| Declines ODDS (%) | 2 days ago 86% | 13 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 80% | 2 days ago 90% |
| Aroon ODDS (%) | 1 day ago 85% | 2 days ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ATYR’s FA Score shows that 1 FA rating(s) are green while KPRX’s FA Score has 1 green FA rating(s).
- ATYR’s FA Score: 1 green, 4 red.
- KPRX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ATYR’s TA Score shows that 2 TA indicator(s) are bullish while KPRX’s TA Score has 3 bullish TA indicator(s).
- ATYR’s TA Score: 2 bullish, 2 bearish.
- KPRX’s TA Score: 3 bullish, 6 bearish.
Price Growth
ATYR (@Biotechnology) experienced а -13.82% price change this week, while KPRX (@Biotechnology) price change was -4.86% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.
Reported Earning Dates
ATYR is expected to report earnings on Nov 05, 2026.
KPRX is expected to report earnings on Nov 06, 2026.
Industries' Descriptions
@Biotechnology (-0.45% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
KPRX and
Correlation & Price change
A.I.dvisor tells us that KPRX and ABVX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KPRX and ABVX's prices will move in lockstep.
| Ticker / NAME | Correlation To KPRX | 1D Price Change % | ||
|---|---|---|---|---|
| KPRX | 100% | -1.26% | ||
| ABVX - KPRX | 31% Poorly correlated | +5.83% | ||
| AKTX - KPRX | 30% Poorly correlated | +1.75% | ||
| MTVA - KPRX | 30% Poorly correlated | +4.88% | ||
| TCRT - KPRX | 29% Poorly correlated | -5.11% | ||
| ATYR - KPRX | 29% Poorly correlated | +0.93% | ||
More | ||||